全文获取类型
收费全文 | 1227011篇 |
免费 | 83749篇 |
国内免费 | 2012篇 |
专业分类
耳鼻咽喉 | 17279篇 |
儿科学 | 38968篇 |
妇产科学 | 31756篇 |
基础医学 | 172882篇 |
口腔科学 | 32855篇 |
临床医学 | 110112篇 |
内科学 | 235695篇 |
皮肤病学 | 27027篇 |
神经病学 | 96947篇 |
特种医学 | 48453篇 |
外国民族医学 | 214篇 |
外科学 | 186349篇 |
综合类 | 23780篇 |
现状与发展 | 4篇 |
一般理论 | 459篇 |
预防医学 | 86127篇 |
眼科学 | 28711篇 |
药学 | 96317篇 |
7篇 | |
中国医学 | 2884篇 |
肿瘤学 | 75946篇 |
出版年
2019年 | 10281篇 |
2018年 | 14326篇 |
2017年 | 11091篇 |
2016年 | 12623篇 |
2015年 | 14352篇 |
2014年 | 19843篇 |
2013年 | 29376篇 |
2012年 | 40724篇 |
2011年 | 43270篇 |
2010年 | 25165篇 |
2009年 | 23523篇 |
2008年 | 40346篇 |
2007年 | 43194篇 |
2006年 | 43408篇 |
2005年 | 42078篇 |
2004年 | 40306篇 |
2003年 | 38498篇 |
2002年 | 37160篇 |
2001年 | 61304篇 |
2000年 | 62365篇 |
1999年 | 52045篇 |
1998年 | 13616篇 |
1997年 | 11916篇 |
1996年 | 11582篇 |
1995年 | 11710篇 |
1994年 | 10594篇 |
1993年 | 10026篇 |
1992年 | 38698篇 |
1991年 | 37155篇 |
1990年 | 36509篇 |
1989年 | 35033篇 |
1988年 | 31621篇 |
1987年 | 30646篇 |
1986年 | 28988篇 |
1985年 | 27303篇 |
1984年 | 20277篇 |
1983年 | 17151篇 |
1982年 | 10309篇 |
1981年 | 9046篇 |
1979年 | 17705篇 |
1978年 | 12211篇 |
1977年 | 10927篇 |
1976年 | 9476篇 |
1975年 | 10569篇 |
1974年 | 12178篇 |
1973年 | 11697篇 |
1972年 | 11094篇 |
1971年 | 10334篇 |
1970年 | 9447篇 |
1969年 | 9114篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
33.
34.
European Journal of Epidemiology - Higher parental age at childbearing has generated much attention as a potential risk factor for birth disorders; however, previous research findings are mixed.... 相似文献
35.
36.
37.
L.S. Becker S.K. Maschke C.L.A. Dewald T.C. Meine H.B.M. Winther M.M. Kirstein R. Kloeckner B.C. Meyer F. Wacker J.B. Hinrichs 《Clinical radiology》2021,76(2):160.e27-160.e33
38.
39.
40.
Balázs Nemes Réka P. Szabó Dávid Péntek Ildikó Nagy Gergely Ivády Bettina Kárai Eszter Szánthó Zsuzsa Hevessy Sándor Sipka Gergő J. Szőllősi Sándor Baráth 《Transplantation proceedings》2021,53(5):1423-1432
IntroductionThe usage of extended-criteria donors (ECD) became a routinely accepted manner in the last decade. ECD is a potential risk factor for antibody-mediated rejection. Analysis of lymphocyte subsets might be a complementary diagnostic toolkit because there is limited knowledge about this term.MethodBetween May 12, 2016, and September 4, 2019, a total of 130 patients who had undergone kidney transplant were investigated. Patients were divided in ECD and standard criteria donor (SCD) groups. Blood samples were collected before the operation, then in the first week and after 30, 60, 180, and 365 days. Besides routine laboratory tests, multicolor flow cytometry was performed for lymphocyte subsets.ResultsECD grafts were transplanted to older recipients. The number of CD4+ cells increased in the SCDs from the first week to until the end of first month, and then decreased. The number of CD4+ cells decreased from the beginning of the study until the end of first year to 66% of its original value in ECDs. At the first month, the number of CD19+ cells was higher in SCD compared with ECD cases; the number then decreased in both groups. T-regulatory cells had a drop at the first week that lasted until the first month. A bigger increase in SCD and a moderate increase in ECD group were then observed. The kinetics of CD19+ and CD19+ naive cells are similar in the ECD and SCD groups. In the SCD group, cell count decreased in both CD19+ (13%) and CD19+ naive (12%) between third and sixth month. The count of CD19+ cells decreased by 9%, but the count of CD19+ naive cells increased by 11% between the sixth month and first year.DiscussionThe prolonged postoperative uremic state caused by the poorer initial function, together with an aging immune system, explains the weaker immune response in ECD patients, which may be the cause of the decreased number of memory and regulatory T cells. Older patients with an ECD graft need a tailored, personalized, and less aggressive immunosuppressive treatment. 相似文献